TY  - CONF
AU  - Mitrović, Bojan
AU  - Samardžić, Vladimir
AU  - Gluvić, Zoran
AU  - Tomasević, Ratko
AU  - Obradović, Milan
AU  - Sudar-Milovanović, Emina
AU  - Isenović, Esma R.
PY  - 2021
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/12030
AB  - Introduction  Non-alcoholic fatty liver disease (NAFLD) is a component of metabolic syndrome (MetS). Hence, it is frequently associated with type 2 diabetes mellitus (T2DM). The low-grade inflammation associated with NAFLD usually explained the changes in serum iron metabolism. This study aims to assess the link between liver steatosis severity and serum iron, ferritin, and transferrin levels.  Material and methods  A case-control study involved 30 non-obese subjects (BMI 18.5–30 kg/m2), who suffered from T2DM for less than 5 years. Such subjects are regularly under treatment by metformin (M) and sulphonylurea (SU) derivates. Liver steatosis severity is determined by ultrasonography and presented as grades 1, 2, and 3 (initial, moderate, and advanced liver steatosis), respectively, according to Singh et al. criteria (Singh et al. Indian J Endocr Metab 2013;17: 990–5).  Results  In the observed population, 14 (47%), 11 (36%), and 5 (17%) subjects are determined to grade 1, 2, and 3 liver steatosis severity groups, respectively. The mean values of iron homeostasis markers have not differed from normal values. Liver steatosis severity grades positively correlated with serum ferritin levels, and this correlation is not revealed in the cases with serum iron and transferrin levels.  Conclusion  The low grade of liver steatosis has predominated in non-obese T2DM subjects under treatment with M and SU, irrespective of glycemic control quality. An increase in liver steatosis severity follows the ascending trend of ferritin levels. Further studies are needed to elucidate the impact of the quality of T2DM control on liver steatosis severity and iron metabolism markers.
C3  - Endocrine Abstracts
T1  - Serum ferritin levels correlate with ultrasonography-determined liver steatosis severity in type 2 diabetes patients with NAFLD
DO  - 10.1530/endoabs.73.AEP294
ER  - 

@conference{
author = "Mitrović, Bojan and Samardžić, Vladimir and Gluvić, Zoran and Tomasević, Ratko and Obradović, Milan and Sudar-Milovanović, Emina and Isenović, Esma R.",
year = "2021",
abstract = "Introduction  Non-alcoholic fatty liver disease (NAFLD) is a component of metabolic syndrome (MetS). Hence, it is frequently associated with type 2 diabetes mellitus (T2DM). The low-grade inflammation associated with NAFLD usually explained the changes in serum iron metabolism. This study aims to assess the link between liver steatosis severity and serum iron, ferritin, and transferrin levels.  Material and methods  A case-control study involved 30 non-obese subjects (BMI 18.5–30 kg/m2), who suffered from T2DM for less than 5 years. Such subjects are regularly under treatment by metformin (M) and sulphonylurea (SU) derivates. Liver steatosis severity is determined by ultrasonography and presented as grades 1, 2, and 3 (initial, moderate, and advanced liver steatosis), respectively, according to Singh et al. criteria (Singh et al. Indian J Endocr Metab 2013;17: 990–5).  Results  In the observed population, 14 (47%), 11 (36%), and 5 (17%) subjects are determined to grade 1, 2, and 3 liver steatosis severity groups, respectively. The mean values of iron homeostasis markers have not differed from normal values. Liver steatosis severity grades positively correlated with serum ferritin levels, and this correlation is not revealed in the cases with serum iron and transferrin levels.  Conclusion  The low grade of liver steatosis has predominated in non-obese T2DM subjects under treatment with M and SU, irrespective of glycemic control quality. An increase in liver steatosis severity follows the ascending trend of ferritin levels. Further studies are needed to elucidate the impact of the quality of T2DM control on liver steatosis severity and iron metabolism markers.",
journal = "Endocrine Abstracts",
title = "Serum ferritin levels correlate with ultrasonography-determined liver steatosis severity in type 2 diabetes patients with NAFLD",
doi = "10.1530/endoabs.73.AEP294"
}

Mitrović, B., Samardžić, V., Gluvić, Z., Tomasević, R., Obradović, M., Sudar-Milovanović, E.,& Isenović, E. R.. (2021). Serum ferritin levels correlate with ultrasonography-determined liver steatosis severity in type 2 diabetes patients with NAFLD. in Endocrine Abstracts.
https://doi.org/10.1530/endoabs.73.AEP294

Mitrović B, Samardžić V, Gluvić Z, Tomasević R, Obradović M, Sudar-Milovanović E, Isenović ER. Serum ferritin levels correlate with ultrasonography-determined liver steatosis severity in type 2 diabetes patients with NAFLD. in Endocrine Abstracts. 2021;.
doi:10.1530/endoabs.73.AEP294 .

Mitrović, Bojan, Samardžić, Vladimir, Gluvić, Zoran, Tomasević, Ratko, Obradović, Milan, Sudar-Milovanović, Emina, Isenović, Esma R., "Serum ferritin levels correlate with ultrasonography-determined liver steatosis severity in type 2 diabetes patients with NAFLD" in Endocrine Abstracts (2021),
https://doi.org/10.1530/endoabs.73.AEP294 . .

TY  - JOUR
AU  - Gluvić, Zoran
AU  - Lacković, Milena
AU  - Samardžić, Vladimir
AU  - Mitrović, Bojan
AU  - Mladenović, Violeta
AU  - Obradović, Milan
AU  - Jevremović, Danimir
AU  - Isenović, Esma R.
PY  - 2019
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/12027
AB  - Congenital adrenal hyperplasia (CAH) is a rare autosomal recessive disorder with mutations in genes involved in cortisol and aldosterone production. Based on overall 21-OHase activity, CAH is divided into classic (C-CAH) and non-classic (NC-CAH). Females who suffered from NC-CAH have had increased infertility rates and higher miscarriage susceptibility. The treatment of CAH in pregnancy is still debatable. We present 22-years-old pregnant female (seventh week of gestation), who is currently under dexamethasone (DEX) since almost seven years for NC-CAH. At presentation, she is normotensive, non-obese, with no signs of hirsutism and Cushing syndrome. Seven days after the first visit, an endocrinologist makes informative talk with the patient and her mother about NC-CAH, pregnancy, and drugsassociated risks. Current Clinical Practice Guideline for CAH treatment suggests the use of protocols approved by Institutional Review Boards at Centers experienced in CAH treatment. In women with CAH who are planning a pregnancy, a close relationship between endocrinologist, reproductive gynaecologist and molecular biologist is of great interest. Prenatal management with DEX is advised in particular circumstances. In remaining, the switch from DEX to other glucocorticoids that do not penetrate placenta is advised
T2  - Clinical Medical Reviews and Case Reports
T1  - Management of Non-Classic Congenital Adrenal Hyperplasia in Pregnant Woman - Non-Referral Center Experience- Case Report
VL  - 6
IS  - 2
DO  - 10.23937/2378-3656/1410257
ER  - 

@article{
author = "Gluvić, Zoran and Lacković, Milena and Samardžić, Vladimir and Mitrović, Bojan and Mladenović, Violeta and Obradović, Milan and Jevremović, Danimir and Isenović, Esma R.",
year = "2019",
abstract = "Congenital adrenal hyperplasia (CAH) is a rare autosomal recessive disorder with mutations in genes involved in cortisol and aldosterone production. Based on overall 21-OHase activity, CAH is divided into classic (C-CAH) and non-classic (NC-CAH). Females who suffered from NC-CAH have had increased infertility rates and higher miscarriage susceptibility. The treatment of CAH in pregnancy is still debatable. We present 22-years-old pregnant female (seventh week of gestation), who is currently under dexamethasone (DEX) since almost seven years for NC-CAH. At presentation, she is normotensive, non-obese, with no signs of hirsutism and Cushing syndrome. Seven days after the first visit, an endocrinologist makes informative talk with the patient and her mother about NC-CAH, pregnancy, and drugsassociated risks. Current Clinical Practice Guideline for CAH treatment suggests the use of protocols approved by Institutional Review Boards at Centers experienced in CAH treatment. In women with CAH who are planning a pregnancy, a close relationship between endocrinologist, reproductive gynaecologist and molecular biologist is of great interest. Prenatal management with DEX is advised in particular circumstances. In remaining, the switch from DEX to other glucocorticoids that do not penetrate placenta is advised",
journal = "Clinical Medical Reviews and Case Reports",
title = "Management of Non-Classic Congenital Adrenal Hyperplasia in Pregnant Woman - Non-Referral Center Experience- Case Report",
volume = "6",
number = "2",
doi = "10.23937/2378-3656/1410257"
}

Gluvić, Z., Lacković, M., Samardžić, V., Mitrović, B., Mladenović, V., Obradović, M., Jevremović, D.,& Isenović, E. R.. (2019). Management of Non-Classic Congenital Adrenal Hyperplasia in Pregnant Woman - Non-Referral Center Experience- Case Report. in Clinical Medical Reviews and Case Reports, 6(2).
https://doi.org/10.23937/2378-3656/1410257

Gluvić Z, Lacković M, Samardžić V, Mitrović B, Mladenović V, Obradović M, Jevremović D, Isenović ER. Management of Non-Classic Congenital Adrenal Hyperplasia in Pregnant Woman - Non-Referral Center Experience- Case Report. in Clinical Medical Reviews and Case Reports. 2019;6(2).
doi:10.23937/2378-3656/1410257 .

Gluvić, Zoran, Lacković, Milena, Samardžić, Vladimir, Mitrović, Bojan, Mladenović, Violeta, Obradović, Milan, Jevremović, Danimir, Isenović, Esma R., "Management of Non-Classic Congenital Adrenal Hyperplasia in Pregnant Woman - Non-Referral Center Experience- Case Report" in Clinical Medical Reviews and Case Reports, 6, no. 2 (2019),
https://doi.org/10.23937/2378-3656/1410257 . .